

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN	ALGENPANTUCEL-L
PRONUNCIATION	al" jen pan too' sel - el
THERAPEUTIC CLAIM	Treatment of pancreatic cancer

CHEMICAL DESCRIPTION

This whole cell immunotherapy product consists of equal doses of two allogeneic human pancreatic cell lines (HAPa-1 and HAPa-2) engineered to express the murine alpha-(1,3) galactosyltransferase gene.

TRADEMARK	HyperAcute®-Pancreas Immunotherapy
MANUFACTURER	NewLink Genetics
CODE DESIGNATION	HAPa
UNII	I6HAD3HP89